Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has decided not to pursue further development of the pharmaceuticals pipeline project Aurograb, an add-on therapy to antibiotics that was being assessed for use in treating deep-seated staphylococcal infections, following a review of recent Phase II clinical data showing a lack of efficacy.
Subscribe to our email newsletter
According to the company, an intangible asset impairment charge of approximately $235 million, which reflects the full amount allocated to this project, will be taken in the third quarter of 2008 in the pharmaceuticals division.
Novartis gained the rights to this compound in 2006 through the acquisition of NeuTec Pharma.
Phase III clinical trials and submission preparations continue for Mycograb, another development compound acquired with NeuTec that is being assessed as an add-on therapy to antifungal agents in treating invasive candidiasis and other severe fungal infections.